Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA1X5W
|
|||
| Drug Name |
INBRX-105
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Inhibrx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | Agonist | [2] |
| Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Cell adhesion molecules (CAMs) | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | TCR Signaling Pathway | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03809624) Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Inhibrx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.